A 12-month program combining the weight loss drug semaglutide, exercise therapy, and nutrition counseling significantly improved walking speed by 18 percent in 22 adults with obesity and joint problems, according to a 2026 research study. Surprisingly, the walking improvements were not directly caused by weight loss alone, suggesting the combination of medication, exercise, and counseling works together to restore mobility and reduce pain.
A new study followed 22 Japanese adults with obesity and joint problems for a year as they received treatment with the weight loss drug semaglutide, nutrition counseling, and exercise guidance. Gram Research analysis found that participants not only lost weight but also significantly improved their walking speed and reduced pain. Surprisingly, the improvements in walking ability weren’t directly tied to how much weight they lost, suggesting that the combination of medication, exercise, and counseling works together in ways scientists are still discovering. People who started with the slowest walking speeds saw the biggest improvements.
Key Statistics
A 2026 observational study of 22 Japanese adults found that a multidisciplinary obesity program including semaglutide improved walking speed from 0.77 to 0.91 meters per second, an 18 percent improvement, over 12 months.
According to research reviewed by Gram, participants in the obesity management program lost an average of 7.7 kilograms and experienced significant pain reduction, with improvements in walking speed occurring independently of weight loss.
A 2026 study of 22 adults with obesity and musculoskeletal disorders found that those with the slowest baseline walking speeds showed the greatest improvements after 12 months of combined semaglutide, exercise, and nutrition treatment.
The Quick Take
- What they studied: Whether a combination treatment program using the weight loss drug semaglutide, exercise, and nutrition counseling could improve how fast people with obesity and joint problems could walk
- Who participated: 22 adults in Japan who had obesity and musculoskeletal disorders (problems with joints, muscles, or bones) and completed the full 12-month program
- Key finding: Walking speed improved by about 18 percent on average, from 0.77 meters per second to 0.91 meters per second. This improvement happened even though it wasn’t directly caused by weight loss alone
- What it means for you: If you have obesity and joint pain, a comprehensive treatment approach combining medication, exercise, and nutrition support may help you move better and feel less pain. However, this was a small study, so talk with your doctor about whether this approach is right for your situation
The Research Details
This was a real-world observational study, meaning researchers looked back at medical records from people who had already completed a 12-month obesity treatment program. The program combined three main components: semaglutide injections (a medication that helps reduce appetite), nutrition counseling sessions every two months, and guided exercise sessions with a physical therapist. Researchers measured how fast participants could walk, their body weight, pain levels, daily step counts, muscle strength, and body composition at the start and end of the year.
The study design is sometimes called retrospective because the researchers reviewed what had already happened rather than assigning people to different treatments. This approach reflects real clinical practice, showing what actually happens when patients receive this combination treatment in everyday medical settings. The researchers focused on gait speed, which is the normal walking pace a person uses in daily life, as their main outcome measure.
Understanding how obesity treatments affect physical function is important because many people with obesity also have joint and muscle problems that limit their movement. Previous research showed that semaglutide causes weight loss, but scientists didn’t know much about whether it actually helps people move better in real-world settings. This study matters because it measures actual walking ability rather than just weight on a scale, which is what affects quality of life for patients with joint problems.
This study has some important limitations to consider. The sample size was small (only 22 people), which means the results may not apply to larger populations. There was no control group for comparison, so we cannot be completely certain the improvements came from the treatment rather than other factors. The study was conducted in Japan with Japanese adults, so results may differ in other populations. However, the study did measure objective outcomes like actual walking speed rather than relying on patient reports, which strengthens the reliability of those measurements
What the Results Show
Participants lost an average of 7.7 kilograms over the 12 months, with body weight dropping from 89.2 kilograms to 81.5 kilograms. More importantly for daily function, their walking speed improved significantly from 0.77 meters per second to 0.91 meters per second, representing an 18 percent improvement. This means participants could walk noticeably faster and with better mobility after the program.
Pain scores also improved substantially during the year, indicating that participants experienced less joint and muscle pain. The improvements in walking speed were particularly striking in people who started with the slowest walking speeds, suggesting that those with the most mobility problems benefited the most from the treatment program.
One surprising finding was that the improvement in walking speed was not directly connected to weight loss. The correlation between weight loss and walking speed improvement was very weak (r=0.22), meaning that people who lost more weight didn’t necessarily walk faster. Similarly, pain reduction wasn’t directly linked to walking speed improvement. This suggests that the benefits come from the combination of all three components working together: the medication, the exercise program, and the nutrition support.
Beyond walking speed, researchers measured several other outcomes. Daily step counts increased, indicating that participants were more active overall. Muscle function improved, suggesting that the exercise component of the program helped build strength. Body composition changed favorably, meaning participants lost fat while preserving or building muscle mass. These secondary outcomes support the idea that the multidisciplinary approach addresses multiple aspects of health beyond just weight reduction.
Previous research has shown that semaglutide effectively reduces body weight, typically causing 10 to 15 percent weight loss. This study confirms that weight loss occurred but adds new information by showing that physical function improvements may not depend entirely on weight loss. Earlier studies on obesity and mobility suggested that weight loss alone might improve walking ability, but this research suggests that exercise and medication work together in ways that benefit movement even when weight loss is modest. The finding that people with worse baseline mobility improved the most aligns with some previous research on exercise interventions in people with obesity.
The study included only 22 participants, which is a small number that limits how much we can generalize the findings to larger populations. There was no comparison group of people who received standard care without semaglutide, so we cannot definitively say the drug caused the improvements rather than the exercise and nutrition counseling alone. The study was conducted in Japan, so results may differ in other countries with different populations and healthcare systems. The study was retrospective, meaning researchers looked at past records rather than following people forward in time. Finally, we do not know how long the improvements lasted after the 12-month program ended
The Bottom Line
If you have obesity and joint or muscle problems, consider asking your doctor about a comprehensive treatment program that combines medication (like semaglutide), regular physical therapy or exercise, and nutrition counseling. This approach appears to improve walking ability and reduce pain. However, this recommendation is based on a small study, so discuss your individual situation with your healthcare provider. The evidence is moderate in strength because the study was small but did measure real-world outcomes
This research is most relevant for adults with obesity who also have musculoskeletal disorders, joint pain, or mobility limitations. It may be particularly helpful for people whose main concern is improving their ability to move and function in daily life, not just losing weight. People with severe joint problems, those unable to exercise, or those who cannot tolerate semaglutide should discuss alternative approaches with their doctors. The findings may be less applicable to people without joint problems or those in countries with different healthcare systems
Based on this study, participants saw improvements over a 12-month period. Walking speed improvements appeared to develop gradually throughout the year as participants engaged in regular exercise and received medication and nutrition support. Most people would likely need at least several months to notice meaningful changes in their mobility and pain levels. Individual results vary, and some people may see benefits sooner while others take longer
Frequently Asked Questions
Does semaglutide help you walk better if you have joint problems?
A 2026 study found that semaglutide combined with exercise and nutrition counseling improved walking speed by 18 percent in people with obesity and joint problems. However, the walking improvements weren’t directly caused by weight loss alone, suggesting the medication works best as part of a comprehensive treatment program.
Can you improve mobility without losing a lot of weight?
Research shows that a combination of medication, exercise, and nutrition support can significantly improve walking ability and reduce pain even with modest weight loss. In this study, walking speed improvements were not strongly connected to how much weight participants lost, suggesting multiple factors contribute to better mobility.
Who benefits most from obesity treatment programs?
According to a 2026 study, people with the worst baseline mobility and slowest walking speeds showed the greatest improvements from a 12-month multidisciplinary program. This suggests that those with the most significant movement limitations may benefit most from comprehensive obesity treatment combining medication, exercise, and nutrition support.
How long does it take to walk better after starting obesity treatment?
The study tracked improvements over 12 months, suggesting meaningful changes in walking ability develop gradually over several months of consistent treatment. Individual results vary, but most people would likely need at least a few months of regular exercise, medication, and nutrition counseling to notice significant improvements in mobility.
Should I focus on weight loss or improving my ability to move?
Research suggests both matter, but they may be separate goals. A 2026 study found that walking speed improvements occurred independently of weight loss in people receiving comprehensive obesity treatment. Discuss with your doctor whether improving mobility and reducing pain should be primary goals alongside weight management.
Want to Apply This Research?
- Track your walking speed weekly by timing how long it takes to walk a fixed distance (like 100 meters or the length of your street). Record this in your app along with your pain level on a scale of 0 to 10 and your daily step count from a fitness tracker. This gives you three measurable indicators of progress beyond just weight
- Use the app to schedule and log your exercise sessions with a physical therapist or on your own, set reminders for nutrition counseling appointments, and track your medication adherence with semaglutide injections. Create a weekly goal for step count and walking distance to gradually increase your activity level
- Set up monthly check-ins in your app to review trends in walking speed, pain scores, and activity levels. Compare your progress month to month rather than focusing only on weight. If you notice walking speed plateaus after several months, discuss with your doctor whether adjustments to exercise intensity or medication dosage might help. Track how your mobility affects daily activities like climbing stairs or shopping to see real-world improvements
This research describes findings from a small observational study of 22 participants and should not be considered definitive medical advice. Semaglutide is a prescription medication with potential side effects and requires medical supervision. Before starting any obesity treatment program, weight loss medication, or new exercise regimen, especially if you have joint problems, musculoskeletal disorders, or other health conditions, consult with your healthcare provider. Individual results vary, and what worked for study participants may not work the same way for you. This article is for educational purposes and does not replace professional medical diagnosis or treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.